Sharon Hutchison

Sharon Hutchison

Auto-generated profile, based on publicly available information

Sharon Hutchison

Centre for Biophotonics, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2011 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SHSharon Hutchison
Sharon Hutchison
RBRobert A. Benson
Robert A. Benson
VGVivienne B. Gibson
Vivienne B. Gibson
APAbigail H. Pollock
Abigail H. Pollock
PGPaul Garside
Paul Garside
JBJames M. Brewer
James M. Brewer
Alum adjuvants have been in continuous clinical use for more than 80 yr. While the prevailing theory has been that depot formation and the associated slow release of antigen and/or inflammation are responsible for alum enhancement of antigen presentation and subsequent T‐ and B‐cell responses, this has never been formally proven. To examine antigen persistence, we used the chimeric fluorescent protein EαGFP, which allows assessment of antigen presentation in situ , using the Y‐Ae antibody. We demonstrate that alum and/or CpG adjuvants induced similar uptake of antigen, and in all cases, GFP signal did not persist beyond 24 h in draining lymph node antigen‐presenting cells. Antigen presentation was first detectable on B cells within 6‐12 h of antigen administration, followed by conventional dendritic cells (DCs) at 12‐24 h, then finally plasmacytoid DCs at 48 h or later. Again, alum and/or CpG adjuvants did not have an effect on the magnitude or sequence of this response; furthermore, they induced similar antigen‐specific T‐cell activation in vivo. Notably, removal of the injection site and associated alum depot, as early as 2 h after administration, had no appreciable effect on antigen‐specific T‐and B‐cell responses. This study clearly rules out a role for depot formation in alum adjuvant activity.—Hutchison, S., Benson, R. A., Gibson, V. B., Pollock, A. H., Garside, P., Brewer, J. M. Antigen depot is not required for alum adjuvanticity. FASEB J. 26, 1272‐1279 (2012). www.fasebj.org

1 January 2006 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
Katharine CarterKatharine Carter
Katharine Carter
SHS. Hutchison
S. Hutchison
FHFiona Henriquez
Fiona Henriquez
DLD. LégAré
D. LégAré
MOMarc Ouellette
Marc Ouellette
AMA. B. Mullen
A. B. Mullen
Sequencing studies showed that the γ-glutamylcysteine synthetase (γ-GCS) heavy chain genes from sodium stibogluconate (SSG)-resistant (SSG-R) and SSG-susceptible (SSG-S)Leishmania donovanistrains were identical, indicating that SSG resistance was related to quantitative differences in γ-GCS expression rather than gene interstrain polymorphisms. In vitro infection of murine macrophages with the SSG-R strain, but not the SSG-S strain, down regulated expression of host γ-GCS, which would result in a reduction in intramacrophage glutathione (GSH) levels and promote an oxidative intramacrophage environment. This would inhibit, or minimize, the reduction of SSG pentavalent antimony to its more toxic trivalent form. Macrophage studies showed that the SSG-R strain expressed higher levels of γ-GCS compared to the SSG-S strain, which would result in higher GSH levels, giving increased protection against oxidative stress and facilitating SSG efflux. However a similar differential effect on host and parasite γ-GCS expression was not obtained when using tissues from infected mice. In this case γ-GCS expression was organ and strain dependent for both the host and the parasite, indicating that environmental conditions have a profound effect on γ-GCS expression. Consistent with the proposed mechanism from in vitro studies, increasing tissue GSH levels in the presence of SSG by cotreatment ofL. donovani-infected mice with SSG solution and GSH incorporated into nonionic surfactant vesicles was more effective in reducing liver, spleen, and bone marrow parasite burdens than monotherapy with SSG. Together, these results indicate that SSG resistance is associated with manipulation of both host and parasite GSH levels byL. donovani.

11 October 2007 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
SHS. Hutchison
S. Hutchison
BCB. S. W. Choo-Kang
B. S. W. Choo-Kang
RBR. V. Bundick
R. V. Bundick
ALA. J. Leishman
A. J. Leishman
JBJ. M. Brewer
J. M. Brewer
PGP. Garside
P. Garside
Summary: Asthma is a heterogeneous disease that has been increasing in incidence throughout western societies and cytokines, including proinflammatory tumour necrosis factor alpha (TNF-α), have been implicated in the pathogenesis of asthma. Anti-TNF-α therapies have been established successfully in the clinic for diseases such as rheumatoid arthritis and Crohn's disease. TNF-α-blocking strategies are now being trialled in asthma; however, their mode of action is poorly understood. Based on the observation that TNF-α induces lymph node hypertrophy we have attempted to investigate this as a mechanism of action of TNF-α in airway inflammation by employing two models of murine airway inflammation, that we have termed short and long models, representing severe and mild/moderate asthma, respectively. The models differ by their immunization schedules. In the short model, characterized by eosinophilic and neutrophilic airway inflammation the effect of TNF-α blockade was a reduction in draining lymph node (DLN) hypertrophy, eosinophilia, interleukin (IL)-5 production and immunoglobulin E (IgE) production. In the long model, characterized by eosinophilic inflammation, TNF-α blockade produced a reduction in DLN hypertrophy and IL-5 production but had limited effects on eosinophilia and IgE production. These results indicate that anti-TNF-α can suppress DLN hypertrophy and decrease airway inflammation. Further investigations showed that anti-TNF-α-induced inhibition of DLN hypertrophy cannot be explained by preventing l-selectin-dependent capture of lymphocytes into the DLN. Given that overall TNF blockade was able to suppress the short model (severe) more effectively than the long model (mild/moderate), the results suggest that TNF-α blocking therapies may be more effective in the treatment of severe asthma.

1 October 2005 in Trends in Immunology
Verified
Journal Article
Closed access
BCB Chookang
B Chookang
SHS Hutchison
S Hutchison
MNM Nickdel
M Nickdel
RBR Bundick
R Bundick
ALA Leishman
A Leishman
PGP Garside
P Garside

1 July 2005 in Parasitology
Verified
Journal Article
Closed access
PDF file
Katharine CarterKatharine Carter
Katharine Carter
SHS. Hutchison
S. Hutchison
ABA. Boitelle
A. Boitelle
HMH. W. Murray
H. W. Murray
SSS. Sundar
S. Sundar
AMA. B. Mullen
A. B. Mullen
Co-treatment of mice infected with different strains of Leishmania donovani with a non-ionic surfactant vesicle formulation of buthionine sulfoximine (BSO-NIV), and sodium stibogluconate (SSG), did not alter indicators of Th1 or Th2 responses but did result in a significant strain-independent up-regulation of IL6 and nitrite levels by stimulated splenocytes from treated mice compared to controls. The efficacy of BSO-NIV/SSG treatment was dependent on the host being able to mount a respiratory burst indicating that macrophages are important in controlling the outcome of treatment. In vitro studies showed that SSG resistance was associated with a greater resistance to killing by activated macrophages, treatment with hydrogen peroxide or potassium antimony tartrate. Longitudinal studies showed that a SSG resistant (SSG-R) strain was more virulent than a SSG susceptible (SSG-S) strain, resulting in significantly higher parasite burdens by 4 months post-infection. These results indicate that SSG exposure may favour the emergence of more virulent strains.

6 November 2009 in Immunology
Verified
Journal Article
Open access
PDF file
CRCatherine Rush
Catherine Rush
OMOwain R. Millington
Owain R. Millington
SHSharon Hutchison
Sharon Hutchison
KBKaren Jane Bryson
Karen Jane Bryson
JBJames M. Brewer
James M. Brewer
PGPaul Garside
Paul Garside
Summary: Despite the recent advances in our understanding of the dynamics of the cellular interactions associated with the induction of immune responses, comparatively little is known about the in vivo behaviour of antigen‐experienced T cells upon secondary antigen exposure in either priming or tolerance. Such information would provide an insight into the functional mechanisms employed by memory T cells of distinct phenotypes and provide invaluable knowledge of how a specific tolerogenic or immunogenic state is maintained. Using real‐time imaging to follow the in vivo motility of naïve, primed and tolerized CD4+ T cells and their interactions with dendritic cells (DCs), we demonstrate that each of these distinct functional phenotypes is associated with specific patterns of behaviour. We show that antigen‐experienced CD4+ T cells, whether primed or tolerized, display inherently slower migration, making many short contacts with DCs in the absence of antigen. Following secondary exposure to antigen, primed T cells increase their intensity or area of interaction with DCs whereas contacts between DCs and tolerized T cells are reduced. Importantly, this was not associated with alterations in the contact time between DCs and T cells, suggesting that T cells that have previously encountered antigen are more effective at surveying DCs. Thus, our studies are the first to demonstrate that naïve, primed and tolerized T cells show distinct behaviours before and after secondary antigen‐encounter, providing a novel mechanism for the increased immune surveillance associated with memory T cells. These findings have important consequences for many immunotherapeutics, which aim to manipulate secondary immune responses.